Accelerate biologic discovery with immunogenicity prediction

New biotherapeutic drugs that elicit complex immune responses are revolutionizing the field of IO. Unwanted immune responses can result in severe adverse effects, therefore their early detection is vital. Without it, these adverse effects may cause safety issues and loss of efficacy along the development process. 

Overall immune response detection allows a significant reduction in the possible number of clinical consequences of anti-drug antibody (ADA) responses. 

How to predict immunogenicity for biologics

Options for immunogenicity prediction

Why cell-based in-vitro assays are highly beneficial in immunogenity prediction 

  • Immune response can be monitored directly from blood, PBMCs, or isolated cell subsets 
  • Human primary cells represent a more reliable physiology 
  • No animal testing required 
  • Afford the possibility of testing different HLA types and selected test populations 
  • Minimize the risk of overprediction  

Example cell-based assays: PBMC activation assay, T cell activation/proliferation assay, DC:T assay, MAPPS assay

Currently faced challenges

  • Ficoll-based PBMC and target cell isolation
  • Cell isolation with lots of hands-on time 
  • Time consuming assay setup and analysis
  • Detection of rare responses
  • Cytokine lot-to-lot variation affecting differentiation reproducibility

Explore our solutions for predictive immunogenicity 

We offer support for cell separation, culture, and analysis

Get in touch with us to learn more about our solutions for predictive immunogenicity

General Information

Detailed Information

Please give your details for further inquiries.

* Mandatory field

Questions / Comments